CD24Fc Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)

• Status: Terminated
• Trial end date: 2021-05-27

Summary

This is a phase 2, randomized, double-blinded, placebo-controlled clinical trial. The intervention drug will be CD24Fc (intravenous [IV] infusion). A cohort of 64 patients with HIV on antiretroviral therapy (ART) will be randomized in a 1:1 fashion to be administered 3 doses of CD24Fc (240mg IV infusion) or placebo once every 2 weeks (q2w) during a 4-week window, followed by a 24-week follow-up window to assess the changes in LDL.

• Phase: Phase 2

Details

• Lead Sponsor: OncoImmune, Inc.
• Collaborators: University of Maryland; University of Maryland, Baltimore
• Treatments: Pharmaceutical Solutions